Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Provided By GlobeNewswire
Last update: Oct 10, 2024
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
Read more at globenewswire.com
